Legislation is Aimed at Reducing Opiate Addictions & Overdoses
(TRENTON) – Legislation sponsored by Assembly Democrats Herb Conaway, Jr., M.D., Daniel Benson, Nancy Pinkin, Benjie Wimberly, Joann Downey and Vincent Mazzeo requiring health insurers to cover prescription pain relief medications designed to decrease abuse and addiction gained approval from an Assembly panel on Thursday.
Specifically, the bill (A-1833) would require health insurers to provide health benefits coverage for prescribed abuse-deterrent opioid analgesic drugs.
“As it stands now, deaths from opioid addiction are at epidemic proportions,” said Conaway (D-Burlington), a practicing physician. “Pain treatment, similar to other courses of treatment, can have side effects – including the risk of addiction. As a doctor, my goal is to reduce those risks and make the patient well. Removing the cost barrier to abuse-deterrent opiates will increase the prescribing and use of these high-tech drugs, which have significant potential to reduce dependency and overdoses. We as policymakers should be encouraging the widespread use of abuse-deterrent formulations to protect consumers and lower costs to the health care system. That’s exactly what this bill achieves.”
Abuse-deterrent opioid analgesic drugs are pain medications approved by the U.S. Food and Drug Administration to significantly reduce abuse by making them resistant to crushing, breaking or dissolution so that they cannot be snorted or injected for a quick high–reinforcing the extended-release deterrent mechanism.
“Far too many young people are attracted to the quick high opiates can produce. There are also too many people who have taken opiates at the advice of their doctor for legitimate pain management, only to find themselves unwittingly dependent on them,” said Benson (D-Mercer/Middlesex). “If there’s a safer, less addictive alternative for pain management, we should be supporting and promoting it.”
The sponsors noted that following the introduction of abuse-deterrent extended-release oxycodone in 2010, dispensing of prescription opioid pain medication and prescription opioid overdoses both dropped by nearly 20 percent two years after this change according to an April study published in the Journal of the American Medical Association.
“Prescription painkiller abuse continues to be a major problem in our communities,” said Pinkin (D-Middlesex). “Anything that can possible be done to slow the rampant abuse of prescription narcotics should be done. This bill is a good start.”
“Drug addiction is an illness which many in New Jersey are battling,” said Wimberly (D-Bergen, Passaic). “This legislation is not a cure all for prescription drug abuse. However, this is a step in the right direction. One aimed at helping individuals who are suffering to curb their addiction.”
“This is sorely needed bill, and common sense,” said Downey (D-Monmouth). “We need to use all our tools to combat this addiction scourge, and do so with responsible means such as this one.”
“We need to approach this problem with a variety of solutions,” said Mazzeo (D-Atlantic). “This is another option.”
Under the bill, the following insurers – health, hospital and medical service corporations; commercial individual and group health insurers; health maintenance organizations; health benefits plans issued pursuant to the New Jersey Individual Health Coverage and Small Employer Health Benefits Programs; the State Health Benefits Program; and the School Employees’ Health Benefits Program) – would be required to provide coverage subject to the following requirements:
1) require health insurers to provide coverage on the insurer’s formulary, drug list, or other lists of similar construct, for at least one prescribed abuse-deterrent opioid analgesic drug product per opioid analgesic active ingredient;
2) Cost-sharing for brand name abuse-deterrent opioid analgesic drugs shall not exceed the lowest cost-sharing level applied to brand name non-abuse deterrent opioid drugs covered under the applicable contract; and
3) Cost sharing for generic abuse deterrent opioid analgesic drug products shall not exceed the lowest cost sharing level applied to generic non-abuse deterrent opioid drugs covered under the applicable contract;
4) An increase in patient cost sharing or disincentives for a prescriber or dispenser shall not be allowed to achieve compliance with the bill’s provisions; and
5) Any prior authorization requirements or other utilization review measures for opioid analgesic drugs shall not require first use of non-abuse-deterrent opioid analgesic drugs in order to access opioid analgesic drugs with abuse-deterrent properties.
The bill was approved by the Assembly Appropriations Committee.